Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jun;23(6):3795-3807.
doi: 10.1111/jcmm.14330. Epub 2019 Apr 4.

The role of post-translational modifications in cardiac hypertrophy

Affiliations
Review

The role of post-translational modifications in cardiac hypertrophy

Kaowen Yan et al. J Cell Mol Med. 2019 Jun.

Abstract

Pathological cardiac hypertrophy involves excessive protein synthesis, increased cardiac myocyte size and ultimately the development of heart failure. Thus, pathological cardiac hypertrophy is a major risk factor for many cardiovascular diseases and death in humans. Extensive research in the last decade has revealed that post-translational modifications (PTMs), including phosphorylation, ubiquitination, SUMOylation, O-GlcNAcylation, methylation and acetylation, play important roles in pathological cardiac hypertrophy pathways. These PTMs potently mediate myocardial hypertrophy responses via the interaction, stability, degradation, cellular translocation and activation of receptors, adaptors and signal transduction events. These changes occur in response to pathological hypertrophy stimuli. In this review, we summarize the roles of PTMs in regulating the development of pathological cardiac hypertrophy. Furthermore, PTMs are discussed as potential targets for treating or preventing cardiac hypertrophy.

Keywords: cardiac hypertrophy; heart failure; post-translational modifications (PTMs).

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Ubiquitination‐mediated signalling pathways of cardiac hypertrophy. Ubiquitination plays an important role in cardiac hypertrophy by regulating the TAK1‐JNK1/2/p38, NF‐κB signalling, Ca2+/calmodulin, oxidation stress, ERK signalling pathways. In these pathways, pressure overload or other hypertrophic stimuli can induce E3 ligases or DUBs to activate MAPKs or other signalling pathways, ultimately regulating nuclear transcription factors to promote growth
Figure 2
Figure 2
SUMOylation‐mediated signalling pathway of cardiac hypertrophy. SUMOylation plays an important role in cardiac hypertrophy by regulating the Ca2+/calmodulin, NF‐κB and other signalling pathways
Figure 3
Figure 3
Acetylation‐ and methylation‐mediated signalling pathways of cardiac hypertrophy. Chromatin modifications are essential for regulating gene expression. Gene transcription can be regulated by acetylation and methylation of chromatin histones. Through remodelling the structure of chromatin, epigenetic modifications mediate the accessibility of DNA to regulate gene expression

References

    1. Li L, Xu J, He L, et al. The role of autophagy in cardiac hypertrophy. Acta Biochim Biophys Sin. 2016;48(6):491‐500. - PMC - PubMed
    1. Frieler RA, Mortensen RM. Immune cell and other noncardiomyocyte regulation of cardiac hypertrophy and remodeling. Circulation. 2015;131(11):1019‐1030. - PMC - PubMed
    1. Harvey PA, Leinwand LA. The cell biology of disease: cellular mechanisms of cardiomyopathy. J Cell Biol. 2011;194(3):355‐365. - PMC - PubMed
    1. Oka T, Akazawa H, Naito AT, Komuro I. Angiogenesis and cardiac hypertrophy: maintenance of cardiac function and causative roles in heart failure. Circ Res. 2014;114(3):565‐571. - PubMed
    1. Khoury GA, Baliban RC, Floudas CA. Proteome‐wide post‐translational modification statistics: frequency analysis and curation of the swiss‐prot database. Sci Rep. 2011;1:90. - PMC - PubMed

Publication types

MeSH terms